For example, Google Play saw a logo refresh when it reached 10 years old, and now, just 10 years removed from the most recent Google logo redesign, we’re getting a bit of a refresh. The current ...

Organon's Q1 2025 earnings report showed significant declines across key financial metrics, leading to a drastic 30% drop in share price following a >90% dividend cut. The company's revenue ...

JERSEY CITY, N.J. (AP) — JERSEY CITY, N.J. (AP) — Organon & Co. (OGN) on Thursday reported first-quarter net income of $87 million. The Jersey City, New Jersey-based company said it had net ...

The bisphosphonate, Fosamax, was first approved by the FDA in 1995 for the treatment and prevention of osteoporosis. While Fosamax was initially hailed as a breakthrough treatment, reports began ...

Fosamax is a brand name of the generic drug alendronate. This type of medication helps treat osteoporosis due to menopause or steroid use. It alters bone formation and the breakdown of the bones ...

Fosamax is a brand name of the generic drug alendronate. It helps treat osteoporosis due to menopause or steroid use. It works by altering bone formation and the breakdown of the bones in the body ...

Organon does not currently expect to record any milestone expense in the fourth quarter of 2024. Organon’s fourth quarter and full year 2024 results have not been finalized and are subject to ...

TD Cowen analyst Michael Nedelcovych took over primary coverage of Organon (OGN) with a Hold rating and $19 price target Organon presented business updates that provide some insight into the 2025 ...

The U.S. Court of Appeals for the Third Circuit has rejected arguments that the plaintiffs' claims in the Fosamax litigation should be preempted by U.S. Food and Drug Administration regulations.

Merck referred a request for comment to Organon, which said it "remains confident in the efficacy and safety profile of Fosamax." About 3,115 lawsuits over Fosamax were pending against Merck in ...